GlaxoSmithKline plc (LON:GSK)‘s stock had its “hold” rating reiterated by research analysts at Shore Capital in a research report issued to clients and investors on Thursday.

Several other research analysts also recently weighed in on the company. Citigroup Inc. reaffirmed a “buy” rating on shares of GlaxoSmithKline plc in a research note on Monday, November 7th. Deutsche Bank AG reaffirmed a “hold” rating and set a GBX 1,700 ($21.24) target price on shares of GlaxoSmithKline plc in a research note on Thursday, July 28th. Independent Research GmbH set a GBX 1,800 ($22.49) target price on GlaxoSmithKline plc and gave the stock a “neutral” rating in a research note on Thursday, August 4th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline plc in a research note on Thursday, September 22nd. Finally, Investec began coverage on GlaxoSmithKline plc in a research note on Thursday, October 20th. They set a “buy” rating and a GBX 1,925 ($24.05) target price for the company. Two investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and nine have given a buy rating to the company’s stock. GlaxoSmithKline plc presently has an average rating of “Hold” and a consensus target price of GBX 1,719.38 ($21.48).

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Shares of GlaxoSmithKline plc (LON:GSK) opened at 1517.00 on Thursday. The company has a 50-day moving average price of GBX 1,631.19 and a 200-day moving average price of GBX 1,585.37. GlaxoSmithKline plc has a 12 month low of GBX 1,277.25 and a 12 month high of GBX 1,745.56. The company’s market capitalization is GBX 73.82 billion.

The firm also recently declared a dividend, which will be paid on Thursday, January 12th. Stockholders of record on Thursday, November 3rd will be issued a GBX 19 ($0.24) dividend. The ex-dividend date is Thursday, November 3rd. This represents a dividend yield of 1.17%.

In other news, insider Manvinder Singh Banga acquired 1,750 shares of GlaxoSmithKline plc stock in a transaction that occurred on Wednesday, October 26th. The stock was purchased at an average cost of GBX 1,643 ($20.53) per share, with a total value of £28,752.50 ($35,922.66). Also, insider Sir Andrew P. Witty sold 10,000 shares of GlaxoSmithKline plc stock in a transaction on Thursday, October 27th. The stock was sold at an average price of GBX 1,636 ($20.44), for a total value of £163,600 ($204,397.80).

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Stock Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related stocks with our FREE daily email newsletter.